Research & Development
Supporting development from research to manufacturing
TRB manufacturing
Discover our three manufacturing sites in Switzerland, Argentina and Brazil
Swiss factory: Vouvry
Hyaluronic acid
At TRB’s Swiss industrial site in Vouvry, one production unit focuses on making injectable products based on hyaluronic acid. Designed in line with international standards, the facility ensures the highest levels of safety and quality.
GM1 Ganglioside
The second unit at Vouvry focuses on the extraction and purification of gangliosides. Both this unit and the facilities dedicated to hyaluronic acid processing and formulation were developed by the site’s technical department to meet international standards. Having this expertise on site supports flexibility, integration, and engineering autonomy, with each process undergoing detailed risk analysis by multidisciplinary teams.
The entire production process for gangliosides, including monosialoganglioside, was developed and and scaled up in Vouvry. The procedure consists of cleaning, extraction, and purification steps, resulting in an active GM1 ingredient.
Research & Development
The Vouvry site also has a dedicated R&D unit, which works closely with the production units. This team designs and puts into practice all the innovative methods and procedures used on site. Using state-of-the-art equipment and their specialised expertise in molecular biology, chemical extraction, synthesis, and formulation, the R&D team plays a key role in improving TRB’s products and keeping them at the highest quality.
TRB’s Swiss industrial site, located in Vouvry, brings together production and R&D. It operates to ISO-certified standards and GMP compliance, ensuring quality and reliability.
Argentinian factory: Buenos Aires
Founded in 1992, TRB Argentina has experienced significant growth, with major expansions beginning in the early 2000s. A key milestone in this evolution was the construction of a self-funded warehouse in Pilar in 2015.
Over the past decade, the site has implemented extensive upgrades in both manufacturing and control equipment to strengthen operational efficiency. The facility produces tablets, coated tablets, and hard gelatin capsules across therapeutic areas such as rheumatology, traumatology, endocrinology, and pain management. Its portfolio includes molecules like diacerein, hyaluronic acid, methotrexate, and vitamin D.
All manufacturing activities comply with ANMAT, MERCOSUR, and COFEPRIS quality requirements. As a subsidiary of TRB Chemedica International, the site supports global supply needs and exports products to more than ten countries in America, Europe, and Asia, including China and Thailand.
The plant’s distinctive strengths include strong employee loyalty and a tightly connected workforce that supports stable, reliable production. TRB Argentina applies advanced technologies in capsule manufacturing and control, ensuring consistency and precision across its operations.
The facility’s structure encourages close collaboration, facilitating efficient communication and coordinated problem-solving. Sustainability initiatives, including waste management and recycling, form part of the site’s continuous improvement efforts. These capabilities contribute to the plant’s position as a highly dependable component of the company’s global network.
The site maintains a clear focus on quality, operational discipline and long-term sustainability. These attributes reinforce the plant’s strategic value within TRB International’s global manufacturing framework.
TRB Argentina, founded in 1992, has grown steadily, with major expansions starting in the early 2000s. Over the past decade the site has upgraded its manufacturing and quality-control equipment to improve efficiency.
Brazilian factory: São Paulo
All products are made under strict international standards, meaning that every step of production is carefully controlled and includes physico-chemical, microbiological, and process checks to ensure the quality, safety and traceability of all products.
The plant is run by a skilled technical team that follows TRB’s global quality standards, ensuring there is consistency across international sites, as well as continuous improvement of processes and products.
Sustainability is part of daily operations. The site focuses on proper waste disposal, recycling, and using energy and resources responsibly, showing its commitment to efficiency and innovation.
TRB Pharma Brazil, located in São Paulo, is the factory that produces Artrodar® (diacerein), a leading osteoarthritis medication, as well as other products in the company's range.